企業概要
Dyadic International, Inc. is a biotechnology platform company focused on the development, production, and sale of industrial enzymes and proteins within the United States and international markets. The firm leverages its proprietary C1 platform specifically for pharmaceutical applications, which includes the end-to-end development and production of pharmaceutical products. This entity operates within the broader Healthcare sector, specifically the Biotechnology industry, positioning it as a specialized player in biomanufacturing and drug development rather than a traditional consumer health provider. With a market capitalization of $31.91M and annual revenue of $3.09M, the company maintains a very small scale with no disclosed employee count, indicating a nascent or highly specialized operational footprint. These valuation and revenue figures suggest the company is in an early-stage growth phase where market value is driven more by intellectual property potential and pipeline assets than by established cash flow generation or broad market share.
財務健全性
The company reported revenue of $3.09M over the trailing twelve months, while net income stood at a significant loss of $-7,364,628, revealing a cost structure where expenses heavily outweigh revenue generation. The absence of reported EBITDA highlights that the company has not yet achieved operational profitability or positive cash earnings before interest and taxes. Free cash flow is negative at $-4,524,691, which indicates a consumption of cash reserves to fund operations and growth initiatives, thereby limiting immediate financial flexibility for shareholder returns. Gross margin stands at 24.9%, suggesting that the cost of goods sold consumes the majority of revenue before other expenses are considered. In contrast, the operating margin is negative at -269.6% and the profit margin is -238.3%, indicating that high operating expenses and administrative costs are driving substantial losses relative to sales. The company holds cash of $7.32M against total debt of $5.06M, resulting in a debt-to-equity ratio of 410.63, which reflects a highly leveraged balance sheet relative to equity but suggests sufficient liquidity to cover short-term obligations given the current ratio of 2.68. Return on Equity is -397.8% and Return on Assets is -44.9%, metrics that reveal that management has not yet generated positive returns on the capital invested in the firm, a common characteristic for pre-commercial biotechnology ventures.
バリュエーション評価
The trailing P/E ratio is not available due to negative earnings, while the forward P/E is listed as -2.74, implying that the market prices the stock based on anticipated future earnings rather than historical performance. The price-to-book ratio is 25.76, which indicates a substantial market premium over the company's book value, suggesting that investors are pricing in significant future growth potential or asset value not captured on the balance sheet. The price-to-sales ratio is 10.33, and since EV/EBITDA is not available, these alternative valuation metrics suggest the market is willing to pay a high multiple for every dollar of sales, typical for companies with minimal current profitability. The 52-week high is $1.35 and the 52-week low is $0.65, meaning the current trading price sits at a specific point within this volatility range, reflecting the speculative nature of the asset. The beta value is 1.21, indicating that the stock's price volatility is higher than the broader market, meaning it is expected to experience larger swings in price during periods of market turbulence compared to a standard benchmark index.
Growth & Income
Revenue growth year-over-year is -30.8%, while earnings growth is not available due to the company's negative earnings position, indicating that the business is currently contracting or restructuring its revenue base before achieving profitability. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it reinvests all available earnings and cash flow back into the business to fund research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue contraction and zero dividend distribution, reflecting a high-risk, high-potential strategy where capital is retained to pursue biotechnology milestones rather than providing immediate income. This profile aligns with early-stage biotech firms that prioritize asset development over shareholder yield.